Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 11OTHER_GOV 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 1Lymphoma, B-Cell 1Leukemia, B-Cell 1

Interventions

Surgical Procedures, Operative 2Dexamethasone 2temoporfin 1pomalidomide 1pembrolizumab 1nimotuzumab 1liposomal doxorubicin 1ledipasvir 1ibrutinib 1golimumab 1Vinorelbine 1Tomography, X-Ray Computed 1Thalidomide 1Sofosbuvir 1Rituximab 1Ribavirin 1Radiotherapy 1Radiation 1Paclitaxel 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Mitoxantrone 1Mastectomy 1Irinotecan 1Infliximab 1Immunotherapy, Adoptive 1Hematologic Tests 1Drug Therapy 1Docetaxel 1Diagnostic Imaging 1Dermoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Recurrence × Immunotherapy, Adoptive × Clear all
NCT03881774 2019-03-21

Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies

Henan Cancer Hospital

Phase 1 Unknown
20 enrolled
LymphoidOther hematologic neoplasm

Recurrence, Leukemia, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡